Neurimmune is a Swiss biotechnology company specializing in the development of antibody therapeutics for the treatment of neurodegenerative diseases. Founded in 2007 and headquartered in Schlieren, Zurich, Switzerland, Neurimmune has pioneered a proprietary technology platform for identifying naturally occurring human antibodies with therapeutic potential[@neurimmune].
The company is known for its groundbreaking work on [alpha-synuclein](/proteins/alpha-synuclein) and [tau](/proteins/tau) antibodies, as well as its role in the development of aducanumab (Aduhelm), a monoclonal antibody targeting [amyloid-beta](/proteins/amyloid-beta) plaques in [Alzheimer's disease](/diseases/alzheimers-disease)[@aducanumab2016].
Funding
Private: Funding from Roche, Novo Nordisk partnerships
Neurimmune's pipeline focuses on several key targets in neurodegenerative diseases:
Alzheimer's Disease Programs
...
Overview
Neurimmune is a Swiss biotechnology company specializing in the development of antibody therapeutics for the treatment of neurodegenerative diseases. Founded in 2007 and headquartered in Schlieren, Zurich, Switzerland, Neurimmune has pioneered a proprietary technology platform for identifying naturally occurring human antibodies with therapeutic potential[@neurimmune].
The company is known for its groundbreaking work on [alpha-synuclein](/proteins/alpha-synuclein) and [tau](/proteins/tau) antibodies, as well as its role in the development of aducanumab (Aduhelm), a monoclonal antibody targeting [amyloid-beta](/proteins/amyloid-beta) plaques in [Alzheimer's disease](/diseases/alzheimers-disease)[@aducanumab2016].
Funding
Private: Funding from Roche, Novo Nordisk partnerships
Neurimmune's pipeline focuses on several key targets in neurodegenerative diseases:
Alzheimer's Disease Programs
Aducanumab (Aduhelm): Originally developed by Neurimmune and licensed to Biogen. Anti-amyloid-beta antibody that received accelerated approval from the FDA in 2021. Showed significant reduction of amyloid plaques in Phase 3 EMERGE and ENGAGE trials[@aduhelm].
Status: Withdrawn from market (2024) following Medicare coverage denial
Parkinson's Disease Programs
NI-202: Anti-alpha-synuclein antibody program for [Parkinson's disease](/diseases/parkinsons-disease). Aims to target and clear toxic alpha-synuclein aggregates that are characteristic of PD pathology.
Target: Toxic alpha-synuclein oligomers and fibrils
Stage: Preclinical
Rationale: Block propagation of alpha-synuclein pathology between neurons
NI-203: Next-generation alpha-synuclein antibody with enhanced brain penetration
Stage: Discovery
Features: Optimized FcRn-mediated transport across BBB
Other Programs
AP-101: Anti-amyloid antibody for ALS (amyotrophic lateral sclerosis)
Target: Misfired TDP-43 aggregates
Stage: Preclinical
ALXN2220 (Cliramidug): Anti-ATTR program for transthyretin amyloidosis (in partnership with Alexion)
Target: Transthyretin (TTR) protein aggregates
Stage: Phase 1/2
NI-301: Tau antibody program for Alzheimer's disease
Target: Pathological tau species
Stage: Discovery
Technology Platform
Neurimmune's antibody discovery platform is based on:
Human antibody libraries — Using memory B cells from healthy elderly individuals with exceptional cognitive function
Single B cell sorting — High-throughput isolation of antigen-specific B cells
Functional screening — Identification of antibodies with desirable therapeutic properties
This approach has yielded several clinical-stage antibodies targeting key proteins in neurodegeneration.
Partnerships and Collaborations
Biogen: Major partnership for aducanumab and other programs
Alexion (AstraZeneca): Partnership for ATTR programs
Academic collaborations: Research institutions in Switzerland and internationally
Scientific Advisory Board
Neurimmune maintains a strong scientific advisory board including leading researchers in neurodegeneration, immunology, and antibody therapeutics.
Relevance to Neurodegeneration
Neurimmune represents a key player in the neurodegenerative disease antibody therapeutics space. Their approach of identifying naturally occurring human antibodies provides several advantages:
Reduced immunogenicity: Human-derived antibodies are less likely to trigger immune responses
High affinity and specificity: Optimized through natural selection
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Engineered variants with improved CNS delivery
The company's focus on multiple protein targets ([alpha-synuclein](/proteins/alpha-synuclein), [tau](/proteins/tau), [amyloid-beta](/proteins/amyloid-beta)) positions it at the forefront of multi-target approaches to treating Alzheimer's and Parkinson's diseases[@alphasynuclein2009].
See Also
[Biogen](/companies/biogen) — Partner for aducanumab](/institutions/biogen)
[Prothena](/companies/prothena) — Tau and alpha-syn programs
[AC Immune](/companies/ac-immune) — Swiss biotech with similar platform